Pharma must embrace holistic open partnerships to prosper says E&Y
This article was originally published in Scrip
Executive Summary
While the provision of healthcare is evolving in the current cost-conscious environment, with the obvious impact on pricing and reimbursement, pharma companies need to hasten their drug development processes, if they are to remain sustainable. This is the stark conclusion of the latest annual Beyond Borders report, launched 20 June at BIO 2012, from professional services group Ernst & Young.